Leukemia, Myelodysplasia, Transplantation
Conference Coverage
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
Immunotherapies under investigation in newly diagnosed B-ALL
SAN FRANCISCO – Researchers are testing blinatumomab and inotuzumab ozogamicin as first-line treatment in B-cell acute lymphoblastic leukemia.
Conference Coverage
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
Conference Coverage
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
From the Journals
Several factors may affect immune suppression discontinuation after HCT
Older age, advanced stage disease, having a mismatched unrelated donor, and receiving peripheral blood stem cells from an unrelated donor were...
Conference Coverage
GALACTIC CLL trial: Obinutuzumab consolidation helps eradicate MRD
EDINBURGH – Obinutuzumab consolidation after chemoimmunotherapy for B-CLL was highly effective for eradicating MRD within 6 months post...
From the Journals
Genetic analysis highlights value of germline variants in MDS, AML
Systematic genetic testing for DDX41 mutations may aid in clinical decision making for adults with MDS or AML.
From the Journals
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
From the Journals
Nonmyeloablative conditioning carries lowers infection risk in patients with AML
Patients who received myeloablative conditioning tended to develop infections sooner.
From the Journals
CK doesn’t seem to affect OS in CLL patients taking idelalisib
Data from two clinical trials of idelalisib showed no significant difference in overall survival between patients with and without complex...
News
Calquence earns breakthrough designation for CLL monotherapy
The Bruton tyrosine kinase inhibitor is already approved for the treatment of adults with mantle cell lymphoma who have received at least one...